Jeff Stonebraker

Summary

Affiliation: North Carolina State Unversity
Location: Raleigh, USA
Publications:
1: Stonebraker JS, Bolton-Maggs PH, Michael Soucie J, Walker I, Brooker M. A
study of variations in the reported haemophilia B prevalence around the world.
Haemophilia. 2011 Jun 7. doi: 10.1111/j.1365-2516.2011.02588.x. [Epub ahead of
print] PubMed PMID: .


2: Stonebraker JS, Bolton-Maggs PH, Brooker M, Farrugia A, Srivastava A. A study
of reported factor IX use around the world. Haemophilia. 2011 May;17(3):446-55.
doi: 10.1111/j.1365-2516.2010.02461.x. Epub 2011 Feb 7. PubMed PMID: .


3: Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of
variations in the reported haemophilia A prevalence around the world.
Haemophilia. 2010 Jan;16(1):20-32. Epub 2009 Oct 21. PubMed PMID: .


4: Stonebraker JS, Brooker M, Amand RE, Farrugia A, Srivastava A. A study of
reported factor VIII use around the world. Haemophilia. 2010 Jan;16(1):33-46.
Epub 2009 Oct 21. PubMed PMID: .


5: Stonebraker JS, Amand RE, Bauman MV, Nagle AJ, Larson PJ. Modelling
haemophilia epidemiology and treatment modalities to estimate the unconstrained
factor VIII demand. Haemophilia. 2004 Jan;10(1):18-26. PubMed PMID: .


6: Stonebraker JS, Amand RE, Nagle AJ. A country-by-country comparison of FVIII
concentrate consumption and economic capacity for the global haemophilia
community. Haemophilia. 2003 May;9(3):245-50. PubMed PMID: .

Publications

  1. ncbi request reprint A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia community
    J S Stonebraker
    Bayer Biological Products, 4101 Research Commons, Alexander Drive, Research Triangle Park, NC 27709 3387, USA
    Haemophilia 9:245-50. 2003
  2. ncbi request reprint Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand
    J S Stonebraker
    Bayer HealthCare, Biological Products Division, Research Triangle Park, NC 27709, USA
    Haemophilia 10:18-26. 2004
  3. doi request reprint A study of reported factor VIII use around the world
    J S Stonebraker
    College of Management, North Carolina State University, Raleigh, NC 27695 7229, USA
    Haemophilia 16:33-46. 2010
  4. doi request reprint A study of variations in the reported haemophilia A prevalence around the world
    J S Stonebraker
    College of Management, North Carolina State University, Raleigh, NC 27695 7229, USA
    Haemophilia 16:20-32. 2010
  5. doi request reprint A study of reported factor IX use around the world
    J S Stonebraker
    North Carolina State University, College of Management, Raleigh, NC 27695 7229, USA
    Haemophilia 17:446-55. 2011
  6. doi request reprint A study of variations in the reported haemophilia B prevalence around the world
    J S Stonebraker
    College of Management, North Carolina State University, Raleigh, NC 27695 7229, USA
    Haemophilia 18:e91-4. 2012
  7. doi request reprint Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin
    Jeffrey S Stonebraker
    Department of Business Management, Poole College of Management, North Carolina State University, Raleigh, NC, 27695, USA
    J Clin Immunol 34:233-44. 2014

Collaborators

Detail Information

Publications7

  1. ncbi request reprint A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia community
    J S Stonebraker
    Bayer Biological Products, 4101 Research Commons, Alexander Drive, Research Triangle Park, NC 27709 3387, USA
    Haemophilia 9:245-50. 2003
    ..This article is of importance to policy makers, care givers and patient organizations in planning health-care resources for the treatment of haemophilia...
  2. ncbi request reprint Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand
    J S Stonebraker
    Bayer HealthCare, Biological Products Division, Research Triangle Park, NC 27709, USA
    Haemophilia 10:18-26. 2004
    ..Sufficient and consistent supply of FVIII concentrates and appropriate financing of haemophilia care will allow the clinical benefits of more aggressive treatment regimens such as prophylaxis to be realized...
  3. doi request reprint A study of reported factor VIII use around the world
    J S Stonebraker
    College of Management, North Carolina State University, Raleigh, NC 27695 7229, USA
    Haemophilia 16:33-46. 2010
    ..This information is also important for pharmaceutical manufacturers to adequately plan for increased production of FVIII concentrates...
  4. doi request reprint A study of variations in the reported haemophilia A prevalence around the world
    J S Stonebraker
    College of Management, North Carolina State University, Raleigh, NC 27695 7229, USA
    Haemophilia 16:20-32. 2010
    ..In addition, this information can help manufacturers plan the production of concentrates and prevent future shortages...
  5. doi request reprint A study of reported factor IX use around the world
    J S Stonebraker
    North Carolina State University, College of Management, Raleigh, NC 27695 7229, USA
    Haemophilia 17:446-55. 2011
    ..By improving the data collection and surveillance of FIX use for the treatment of people with haemophilia B, we can identify trends and needs of patients and highlight best treatment practices among countries...
  6. doi request reprint A study of variations in the reported haemophilia B prevalence around the world
    J S Stonebraker
    College of Management, North Carolina State University, Raleigh, NC 27695 7229, USA
    Haemophilia 18:e91-4. 2012
    ..Prevalence data are extremely valuable information for the planning efforts of national healthcare agencies in setting priorities and allocating resources for the treatment of HB...
  7. doi request reprint Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin
    Jeffrey S Stonebraker
    Department of Business Management, Poole College of Management, North Carolina State University, Raleigh, NC, 27695, USA
    J Clin Immunol 34:233-44. 2014
    ..The estimates were performed for common variable immunodeficiency (CVID) and X-linked Agammaglobulinaemia (XLA), the two most commonly studied PIDs using Ig...